SCHEMBL27002006

SCHEMBL27002006

CCCCSc1c(OC)cc(C=O)cc1OC

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 9/20 0.43
▸ TSHR P16473 1/20 0.43
▸ FDPS P14324 1/20 0.41
▸ AR P10275 1/20 0.41
▸ HPGD P15428 3/20 0.41
▸ MAPT P10636 3/20 0.41
▸ L3MBTL1 Q9Y468 2/20 0.40
▸ TRIM24 O15164 1/20 0.40
▸ ALDH5A1 P51649 1/20 0.40
▸ ABAT P80404 1/20 0.40
▸ TDP1 Q9NUW8 1/20 0.40
▸ TRIM33 Q9UPN9 1/20 0.40
▸ MAPK1 P28482 1/20 0.37
▸ AOX1 Q06278 1/20 0.37
▸ SOAT1 P35610 1/20 0.36
▸ CYP1A2 P05177 1/20 0.36
▸ CYP2E1 P05181 1/20 0.36
▸ CYP3A4 P08684 1/20 0.36
▸ CYP2C8 P10632 1/20 0.36
▸ CYP2D6 P10635 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27002045 0.95 ALDH1A1 (0.42) ALDH1A1TSHRFDPSARHPGD
SCHEMBL27002173 0.84 HTR2A (0.45) ALDH1A1TSHRFDPSHPGDMAPT
SCHEMBL27002089 0.84 ALDH1A1 (0.41) ALDH1A1TSHRFDPSHPGDMAPT
SCHEMBL27002188 0.83 HTR2A (0.44) ALDH1A1TSHRFDPSHPGDMAPT
SCHEMBL27002017 0.83 ALDH1A1 (0.40) ALDH1A1TSHRFDPSARHPGD
SCHEMBL11093194 0.83 ALDH1A1 (0.48) ALDH1A1TSHRFDPSHPGDMAPT
SCHEMBL11584615 0.82 ALDH1A1 (0.48) ALDH1A1TSHRFDPSHPGDMAPT
SCHEMBL27002179 0.82 ALDH1A1 (0.40) ALDH1A1TSHRFDPSHPGDMAPT
SCHEMBL27002052 0.81 ALDH1A1 (0.38) ALDH1A1TSHRFDPSHPGDMAPT
SCHEMBL27002026 0.79 AR (0.43) ALDH1A1TSHRFDPSARHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240166618-A1 PHENALKYLAMINES AND METHODS OF MAKING AND USING THE SAME GILGAMESH PHARMACEUTICALS, INC. (US) 2024-05-23 — — US disclosed
CN-117642379-A Phenylalkylamines and methods of making and using the same 吉尔伽美什制药公司 2024-03-01 — — CN disclosed
EP-4305019-A1 PHENALKYLAMINES AND METHODS OF MAKING AND USING THE SAME Gilgamesh Pharmaceuticals, Inc. (US) 2024-01-17 — — EP disclosed
WO-2022192781-A1 PHENALKYLAMINES AND METHODS OF MAKING AND USING THE SAME GILGAMESH PHARMACEUTICALS, INC. (US) 2022-09-15 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240166618-A1 PHENALKYLAMINES AND METHODS OF MAKING AND USING THE SAME PNMT, HTR6, HTR2C ALDH1A1 1077/4885TSHR 3645/4885FDPS 2210/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback